Sports
Analysts Set $35.56 Target Price for Match Group Stock Following Recent Ratings
Match Group Inc. (NASDAQ:MTCH) has received a consensus target price of $35.56 from analysts, reflecting an average rating of “Hold” from the twenty-one ratings firms currently covering the company, according to MarketBeat.com. Among these analysts, sixteen issued a hold rating, while five recommended buying the stock.
Several investment firms have recently updated their assessments of Match Group. For instance, JPMorgan Chase & Co. raised its price target from $28.00 to $33.00 and maintained a “neutral” rating in a research note dated August 6. Similarly, UBS Group increased its price target from $31.00 to $35.00, also assigning a “neutral” rating in a note released on July 23.
Research from Morgan Stanley indicates a decrease in their price target, moving from $35.00 to $34.00 while maintaining an “equal weight” rating as of October 20. Additionally, Evercore ISI adjusted its target upwards from $32.00 to $38.00, giving the stock an “in-line” rating on August 6.
Institutional Investment Trends
Recent changes in institutional investments have also been noteworthy. Smartleaf Asset Management LLC increased its stake in Match Group by 8.2% during the second quarter, now owning 4,307 shares valued at approximately $133,000. Applied Finance Capital Management LLC raised its holdings by 5.1%, resulting in a total of 6,880 shares worth around $215,000.
Other notable changes include Bollard Group LLC, which increased its stake by 0.7%, now holding 54,558 shares valued at approximately $1.685 million. MassMutual Private Wealth & Trust FSB raised its stake by 56.0%, owning 1,008 shares valued at about $31,000. Lastly, Parallel Advisors LLC increased its holdings by 18.5%, bringing total ownership to 2,500 shares valued at approximately $77,000. Currently, institutional investors and hedge funds own 94.05% of Match Group’s stock.
Stock Performance and Dividend Information
As of Friday, October 20, Match Group shares opened at $32.82. The stock shows a 50-day moving average of $35.68 and a 200-day moving average of $32.99. The company has recorded a fifty-two week low of $26.39 and a high of $39.20. Match Group’s market capitalization stands at $7.90 billion, with a price-to-earnings ratio of 16.17 and a PEG ratio of 0.65.
In addition to stock performance, Match Group recently announced a quarterly dividend of $0.19 per share, which was paid to shareholders on October 17. Shareholders of record as of October 3 received this dividend, which translates to an annualized dividend of $0.76 and a yield of 2.3%. The company’s dividend payout ratio is approximately 37.44%.
Match Group, Inc. specializes in dating products and operates a diverse portfolio of brands, including Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and Hakuna. The company’s services are available in over 40 languages, catering to users around the globe.
Overall, Match Group continues to be a significant player in the dating services sector, with ongoing interest from analysts and institutional investors alike.
-
Science2 weeks agoResearchers Challenge 200-Year-Old Physics Principle with Atomic Engines
-
Politics2 weeks agoNHP Foundation Secures Land for 158 Affordable Apartments in Denver
-
World3 days agoBoeing’s Aircraft Production: Assessing Numbers and Challenges
-
Health2 weeks agoNeuroscientist Advocates for Flag Football Until Age 14
-
Lifestyle3 days agoRed Bluff High School’s Elli Nolan Named Rotary Student of the Month
-
Lifestyle2 weeks agoLongtime Friends Face Heartbreak After Loss and Isolation
-
World2 weeks agoGlobal Military Spending: Air Forces Ranked by Budget and Capability
-
Science3 days agoAI Misidentifies Doritos Bag as Gun, Triggers Police Response
-
Business2 weeks agoSpirit Airlines Cuts Workforce with Furloughs for 365 Pilots
-
Politics2 weeks agoIsraeli Air Strikes in Lebanon Kill One, Wound Seven Amid Tensions
-
Top Stories4 days agoUrgent Search for Suspect Who Exposed Himself to Teen Girl
-
Health2 weeks agoFDA Launches Fast-Track Review for Nine Innovative Therapies
